This study is looking at people with advanced solid tumors, which are cancers that have grown or spread in the body and cannot be removed by surgery. The specific types of cancer being studied include lung cancer, head and neck cancer, triple-negative breast cancer, and a certain type of hormone receptor-positive breast cancer. The treatment being tested is BMS-986517, which is given as a solution for infusion directly into a vein. This medication is being studied on its own, without being combined with other treatments.
The purpose of the study is to find out what doses of BMS-986517 are safe and how much people can tolerate in order to choose the best dose for future use, and to check if giving BMS-986517 at the chosen dose continues to be safe for people with specific cancers. The study will also monitor how often side effects occur, including serious side effects and those that might require stopping treatment. Additionally, the study will track whether tumors shrink and how long any responses last, as well as how the medication moves through and is processed by the body.
The study is divided into two parts. The first part focuses on testing different doses to determine which are safe and well tolerated. The second part uses the doses chosen from the first part to further evaluate safety in people with specific types of cancer. Participants will receive the medication through infusion and will be monitored for side effects during the first 21 days and throughout the treatment period, which can last up to 3 years from the first treatment, with additional monitoring for 30 days after the last treatment.
Denmark 
Spain 
